LSBio
IHC-plus™ Monoclonal Mouse anti-Human CD1C Antibody (clone 4C7, IHC, IF, WB)

Anti-CD1C antibody IHC staining of human thymus. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 10 ug/ml.

IHC-plus™ Monoclonal Mouse anti-Human CD1C Antibody (clone 4C7, IHC, IF, WB)

Primary AntibodyLSBio Guarantee
Antibody:Mouse Monoclonal
Applications:Immunofluorescence, Immunohistochemistry (general), Immunohistochemistry, Paraffin, Western Blot
Reactivity:Human
Format:Liquid
See all CD1C antibodies →
$383.00each
Catalog Number: LS-B10059-50

For bulk orders or custom formulations:

Request a Quote

Overview

Description
CD1C antibody LS-B10059 is an unconjugated mouse monoclonal antibody to human CD1C. Validated for IF, IHC and WB. Tested on 20 paraffin-embedded human tissues. Cited in 1 publication.
Application
IF, IHC, IHC-P, WB
Reactivity
Hu
Intended Use
Research Use Only
Guarantees
This product carries the LSBio 100% Guarantee.
Category
Antibodies > Primary Antibodies > Monoclonal Antibodies
Alternative Names
BDCA1 | CD1 | CD1c molecule | CD1C | CD1C antigen, c polypeptide | CD1c antigen | R7
Recommended Dilution: IF/ICC
1:100
Recommended Dilution: IHC-P
10 µg/ml
Recommended Dilution: WB
1:500 - 1:2000
UniProt Number
P29017
SwissProt
P29017

Target

Target
CD1C
Antigen Species
Human
Specificity
Human CD1C
Epitope
Human CD1C
Gene Name
CD1C

Antibody

Host Species
Mouse
Clonality
Monoclonal
Clone
4C7
Origin Species
Human

Immunogen

Immunogen
Full length human recombinant protein of human CD1C(NP_001756) produced in HEK293T cell.
Immunogen Type
Full-Length Recombinant Protein

Format

Conjugate/Label
Unconjugated
Format
Liquid
Formulation
PBS, pH 7.3, 0.02% Sodium Azide, 50% Glycerol, 1% BSA
Concentration
1 mg/mL
Volume
50 Microliter
Animal Free
No
Carrier-Free
No
Preservative
Yes
Purification Method
Protein A/G Affinity

Storage & Handling

Storage Conditions
Store at -20°C. Avoid freeze-thaw cycles.
Recommended Storage Buffer
PBS
Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin. Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin. The Journal of investigative dermatology. 2018 June;138:1301-1310. PubMed: 29391252 PMC: PMC6590516

Request SDS/MSDS

To request an SDS/MSDS form for this product, please contact our Technical Support department at: technical@vectorlabs.com.